A Phase IIa, Double-blind, Randomised, Placebo-controlled, Dose-finding Efficacy and Safety Study of A3309 in Patients With Dyslipidemia.
Phase of Trial: Phase II
Latest Information Update: 19 Oct 2016
At a glance
- Drugs Elobixibat (Primary)
- Indications Dyslipidaemias
- Focus Therapeutic Use
- Sponsors Albireo AB
- 19 Oct 2010 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
- 19 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.